OBJECTIVE Ghrelin is thought to be involved in the regulation of eating behaviour and energy metabolism in acute and chronic feeding states. Circulating plasma ghrelin levels in healthy humans have been found to decrease significantly after oral glucose administration. Because it is suggested that eating behaviour may influence the secretion of ghrelin and insulin in anorexia nervosa (AN), we examined the effect of oral glucose on ghrelin and insulin secretion in subtypes of AN patients. DESIGN AND PATIENTS Twenty female AN patients and 10 age-matched female controls were subjects. The patients were subdivided into two subtypes based on eating behaviour as follows: 11 restricting type (AN-R), nine binge-eating and purging type (AN-BP). Subjects underwent an oral glucose tolerance test at 08·00 h. Blood was collected 0, 30, 60, 120 and 180 min after the glucose load.
Ghrelin is involved in the regulation of GH release (Kojima et al ., 1999; Takaya et al ., 2000) and recently has been found to have other actions, including effects on appetite (Tschöp et al ., 2000; Cummings et al ., 2001; Wren et al ., 2001; Lawrence et al ., 2002) , one heart (Nagaya et al ., 2001) , pancreas (Wierup et al ., 2002) and carbohydrate metabolism . This peptide is an orexigenic peptide that has effects similar to hypothalamic neuropeptides such as neuropeptide Y (NPY; Shintani et al ., 2001 ) and agouti-related protein (AGRP; Nakazato et al ., 2001) . Plasma ghrelin concentrations in the gastric and truncal veins of normal rats increase in response to fasting and decrease upon refeeding (Tschöp et al ., 2000; Dornonville et al ., 2001; Toshinai et al ., 2001) . Circulating plasma ghrelin in healthy humans is found to decrease significantly after oral and intravenous (i.v.) glucose administration . On the other hand, intravenous administration of ghrelin stimulates circulating gastrin and insulin levels in rats (Lee et al ., 2002) . These findings suggest the involvement of ghrelin in the regulation of eating behaviour and energy homeostasis in both acute and chronic feeding states.
The eating disorder anorexia nervosa (AN) is characterized by chronic food restriction and has been found to cause alterations in the release of gastrointestinal peptides (Baranowska et al ., 2000) , including increased circulating ghrelin (Ariyasu et al ., 2001; Otto et al ., 2001) , and causes various metabolic changes such as glucose metabolism (Drossman et al ., 1979) , insulin sensitivity (Zuniga-Guajardo et al ., 1986; Kiriike et al ., 1990; Fukushima et al ., 1993) and insulin resistance (Scheen et al ., 1988) . However, we previously found that after subdividing AN into two subtypes based on guidelines for the differences in eating behaviour as published in the Diagnostic and Statistical Manual of Mental Disorders , 4th edition (DSM-IV; American Psychiatric Association, 1994) there were increased plasma ghrelin levels in AN patients with habitual binge/purge behaviour (AN-BP) when compared to restricting behaviour (AN-R) despite similar body mass indeces (Tanaka et al ., 2003b) . The normal weight of a patient with bulimia nervosa with habitual binge-eating and purging has also been found to increase the ghrelin level . Moreover, carbohydrate metabolism and insulin secretion in eating disorders are considered to be related to nutritional status and eating patterns (Casper et al ., 1988; Johnson et al ., 1994) . These findings suggest that differences in eating behaviour may influence secretion of ghrelin and insulin in AN. Therefore in this study, we measured ghrelin and insulin responses to oral glucose loads in all subjects in order to examine the effect of acute feeding states on ghrelin and insulin secretion, and compared the states between the subtypes of AN patients and healthy controls for the purpose of clarifying the pathophysiology of eating behaviour.
Research design and methods

Subjects
Eleven female AN-R patients, nine female AN-BP patients who met DSM-IV guidelines and 10 age-matched apparently healthy female volunteers (controls) were the subjects in this study. Patients were admitted to our hospitals for inpatient treatment, and were excluded if they had a history of alcohol or substance abuse, or gastrointestinal disease. AN-BP patients had habitual binge-eating and vomiting at least twice a week over the preceding 3 months. Written informed consent was obtained from all participants before starting the study, which proceeded in accordance with the principles of the Declaration of Helsinki. Controls were recruited by advertisement in the local community and were paid for their participation. They had no history of psychiatric illness and metabolic diseases, ate normal diets and were within 10% of ideal body weight.
Protocol
Subjects were given a 75-g / 225-ml glucose solution orally at 08·00 h after an overnight fast. A butterfly needle was inserted into a forearm vein and the catheter was kept patent by a saline infusion in order to collect blood samples efficiently. Blood was collected 0, 30, 60, 120 and 180 min after oral administration. During testing, all subjects remained in a recumbent position and no activity or eating was permitted. We measured body weight at the time blood samples were obtained. The AN patients were assayed within 1 week after admission and before the initiation of active treatment including medications such as psychotropics. The Institutional Committee of Kagoshima University approved the protocol.
Measurements
Plasma glucose was measured by the glucose oxidase method. Serum insulin was determined by an EIA kit (SRL, Inc., Tokyo, Japan). Blood was drawn into chilled tubes containing EDTA2Na (1 mg / ml) and aprotinin (500 U / ml). Plasma ghrelin was measured using radioimmunoassay (RIA) as described elsewhere . In brief, antiserum against the C-terminal region of human ghrelin was raised in New Zealand white rabbits immunized against synthetic human ghrelin[13 -28] that had been coupled with maleimide-activated mariculture keyhole limpet haemocyanin. The antiserum recognized acylated ghrelin and nonacylated ghrelin equally on a molar basis. Human Tyr 0 -ghrelin [13 -28] was radioiodinated by the lactoperoxidase method for use in the assay. Inter-and intra-assay variation was < 8 and < 6%, respectively. The limit of detection of this assay is 12 fmol/ tube of human ghrelin. Two milliliters of plasma was diluted with 2 ml of 0·9% saline and applied to a Sep-Pak C-18 cartridge (Waters, Milford, MA, USA) pre-equilibrated with 0·9% saline. The cartridge was washed first with saline and then with a 0·1% trifluoroacetic acid (TFA) solution and peptides were eluted with a 60% acetonitrile (CH 3 CN) solution containing 0·1% TFA. The eluate was evaporated, reconstituted with RIA buffer and subjected to RIA analysis. A diluted sample or a standard peptide solution (100 µ l) was incubated for 24 h with 100 µ l of the antiserum diluent (final dilution 1/20 000). The tracer solution (16 000 cpm /100 µ l) was added, and the mixture incubated for 24 h. Bound and free ligands were separated by the second antibody method. All procedures were done at 4 ° C. Recovery of human ghrelin added to the plasma was 90·7 ± 4·0% ( n = 6).
Statistics
The subject groups (mean ± SEM) were compared using analysis of variance ( anova ) and a posthoc Scheffé test, when data were normally distributed. The Kruskal-Wallis one-way anova with a chi-square statistic was used to test group differences for the subject characteristic variables because the data distributions were skewed. A P -value of < 0·05 was considered statistically significant.
Results
Physiological characteristics for the subject groups are shown in Table 1 . The mean body mass index ( P < 0·01) and basal serum insulin level ( P < 0·05) in both AN-R and AN-BP were significantly lower than those in controls. Basal plasma glucose levels in AN-R were significantly lower ( P < 0·05) as compared to the control group. Basal plasma ghrelin in both AN-R and AN-BP were significantly higher ( P < 0·01) as compared to controls (Table 1) .
The mean plasma ghrelin concentrations in both controls and AN-BP patients decreased after administration of an oral glucose load, reaching nadirs of 60·2% (74·3 ± 7·9 pmol/ l, mean ± SEM) and 58·1% (204·9 ± 34·3 pmol/l) of basal levels, respectively, 60 min and 120 min after the glucose load, and increasing thereafter. However, the plasma ghrelin level in AN-R patients constantly decreased without reaching the nadir level for 180 minutes (80·0%, 182·4 ± 31·5 pmol/ l; Fig. 1) .
The plasma glucose level 180 min after the glucose load in AN-R was higher than that in controls ( P < 0·05; Fig. 2a ). Though the peak glucose level occurred 60 min after the glucose load in both AN-BP and controls, the peak in AN-R occurred 120 min after the glucose load (Fig. 2a) . After glucose loads in controls, the peak insulin level was found to occur at 60 min (509·2 ± 88·8 pmol/l) while the peaks in AN-BP and AN-R were, respectively, 120 min (319·3 ± 88·8 pmol/ l) and 180 min (418·9 ± 68·4 pmol/ l) after the glucose load (Fig. 2b) .
Discussion
AN-R patients exhibited a constant decreased ghrelin level without reaching a nadir during the test and peaks were delayed for both glucose and insulin as compared to AN-BP and controls. Plasma ghrelin concentrations in healthy humans have been found to decrease significantly after oral and intravenous glucose administration , and it has been suggested that there is delayed glucose absorption due to gastric and duodenal dysmotility in AN-R patients (Stacher et al ., 1986; Buchman et al ., 1994) . However, these results might be caused by impaired regulation of ghrelin secretion as recent studies have shown that plasma ghrelin is not regulated by i.v. administration of glucose, or the combination of glucose and insulin (Caixás et al ., 2002; Schaller et al ., 2003) . A previous study of carbohydrate metabolism (Nozaki et al ., 1994) also showed that initial insulin secretion was decreased in AN patients that had glucose level peaking 90 min or later in response to both oral and intravenous glucose. Because our study found that the glucose peak level in AN-R was 120 min, these findings suggest that AN-R patients might also have β -cell dysfunction in acute feeding states.
AN-BP patients had increased basal ghrelin, decreased basal insulin and a delayed nadir for ghrelin and the peak insulin as compared to controls, although the times for peak glucose were similar to controls. Our recent research (Tanaka et al ., 2003a) suggests that binge-eating with vomiting rather than binge-eating without vomiting may influence ghrelin levels in eating disorders. In bulimia nervosa patients with unstable weight and with binge-eating and frequent vomiting, a blunted insulin response to a glucose load was found. On the other hand, in these patients who were treated successfully by abstaining from binge-eating and vomiting for 4 weeks, there was a similar insulin response to that seen in normal controls (Russell et al ., 1996) . These findings suggest that both abnormal eating behaviour and nutritional Table 1 Physiological characteristics (mean ± SEM) of subject groups AN-R n = 11 AN-BP n = 9 control n = 10 Kruskal-Wallis* P
*The Kruskal-Wallis one-way anova was used to test because the data distributions were skewed. †P < 0·05 v.s. control, using anova and a posthoc Scheffé test. depletion may be the cause of the results found in AN-BP, and that abstaining from binge-eating and vomiting may be important for inpatient treatment of AN-BP patients. The present study suggests that differences in eating behaviour may influence the effect of oral glucose on both ghrelin and insulin secretion in AN patients. A few studies (Stordy et al., 1977; Neuberger et al., 1995) have shown that oral energy intake with nutritional rehabilitation required for weight gain is significantly different between AN subtypes. In particular, AN-R patients required 30 -50% more energy intake than AN-BP (Kaye et al., 1986) . These findings suggest that impaired regulations of both ghrelin and insulin seen with restrictive eating patterns may be the cause of the higher oral energy intake required for weight gain rather than the actual AN-BP behaviour.
Ghrelin, one of the gastric and orexigenic peptides, is found to inhibit the insulin response to the secretagogues glucose, arginine and carbachol (Egido et al., 2002) . In contrast, insulin is one of the anorexigenic peptides and has been shown to decrease plasma ghrelin in humans (Saad et al., 2002) . Ghrelin has also been documented to be present in α-cells, and increase the cytosolic free Ca 2+ concentration in β-cells and stimulate insulin secretion (Date et al., 2002b) . These peptides, which are related to energy metabolism, have been suggested to be regulated through the vagal system (Herath et al., 1999; Masuda et al., 2000; Blat & Malbert, 2001; Date et al., 2002a) . Therefore, we consider the abnormal eating behaviour and nutritional change in AN to have some influence on the relationship between ghrelin and insulin secretion through the vagal system. Finally, our study documents that both the time at the nadir of the plasma ghrelin level and the peak serum insulin level are delayed in AN patients, especially in AN-R as compared to controls. The present study suggests that differences in eating behaviour may influence the effect of oral glucose on both ghrelin and insulin secretion in AN patients before active treatment. Thus, alterations in both nutritional status and eating pattern may induce ghrelin and insulin metabolic changes in both the acute and chronic feeding state. Furthermore, these metabolic changes in the restrictive eating patterns may be related to the pathophysiology of small quantitative meal intake in AN-R patients. 
